Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + axitinib
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Toripalimab + axitinib is a combination therapy consisting of two agents: toripalimab, a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), and axitinib, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs). Toripalimab acts as an immune checkpoint inhibitor by blocking PD-1, thereby enhancing T-cell mediated antitumor immunity. Axitinib inhibits angiogenesis and tumor growth by selectively blocking VEGFRs. This combination has demonstrated synergistic antitumor activity in clinical trials for advanced renal cell carcinoma (RCC) and metastatic mucosal melanoma. In China, it is approved for first-line treatment of intermediate to high-risk unresectable or metastatic RCC. The regimen has also shown promising efficacy in neoadjuvant settings for clear cell RCC and in patients with advanced mucosal melanoma[2][3][4][7][8][9].
- Brand names
- TUOYI
- Other names
- toripalimab plus axitinibtoripalimab combined with axitinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on toripalimab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + axitinib.